Plasmalogens
A class of brain phospholipids depleted in Alzheimer's disease and sold as scallop- or chicken-derived supplements. One randomized trial found benefit only in subgroups, and independent replication is missing.
Evidence last reviewed: August 2026
What the science says
- Subgroup benefit in one randomized trial Limited evidence
A multicenter, double-blind, placebo-controlled trial in patients with mild Alzheimer's disease and mild cognitive impairment found no overall cognitive advantage, with improvement limited to pre-specified subgroups such as younger MCI participants. Blood plasmalogen levels did rise on treatment.
- Open-label data in cognitive impairment Limited evidence
An uncontrolled supplementation study in cognitively impaired adults reported increased blood plasmalogens alongside some cognitive and mobility measures. Without a placebo group these results cannot be separated from practice effects and expectation.
Dosage & safety
Scientific references
- Efficacy and Blood Plasmalogen Changes by Oral Administration of Plasmalogen in Patients with Mild Alzheimer's Disease and Mild Cognitive Impairment: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial
- Targeted Plasmalogen Supplementation: Effects on Blood Plasmalogens, Oxidative Stress Biomarkers, Cognition, and Mobility in Cognitively Impaired Persons
Where to buy
Referral link — this site may earn a commission on purchases.
Related in Brain & cognition
- Vitamin B2 (Riboflavin) Moderate evidence
- Choline Moderate evidence
- Magnesium L-Threonate Limited evidence
- Phosphatidylserine Limited evidence
- Lecithin (Phosphatidylcholine) Limited evidence
- Agmatine Sulfate Limited evidence